| Cat. No. |
Product Name |
Information |
| PC-45862 |
Palbociclib
CDK4/6 inhibitor
|
Palbociclib (PD0332991) is a potent and selective, orally bioavailable inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. |
| PC-42052 |
SNS-032
CDK9 inhibitor
|
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2/CDK7/CDK9 with IC50 of 48 nM/62 nM/4 nM, respectively. |
| PC-42616 |
Dinaciclib
CDK inhibitor
|
Dinaciclib (SCH 727965, MK-7965) is a potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively. |
| PC-45792 |
Roscovitine
CDK inhibitor
|
Roscovitine ((R)-Roscovitine, Seliciclib, CYC202) is a potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively. |
| PC-42036 |
LY3177833
CDC7 inhibitor
|
LY3177833 is a potent and selective CDC7 inhibitor with IC50 of 3.3 nM. |
| PC-42060 |
AZD-5438
CDK1/2/9 inhibitor
|
AZD-5438 (AZD5438) potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively. |
| PC-42425 |
Senexin B
CDK8/CDK19 inhibitor
|
Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM. |
| PC-42527 |
JNJ-7706621
CDK/Aurora inhibitor
|
JNJ-7706621 is a potent, dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively. |
| PC-26368 |
CDK9 inhibitor C35
CDK9 inhibitor
|
CDK9 inhibitor C35 is a potent, selective and orally bioavailable CDK9 inhibitor with IC50 of 17.44 nM, shows 18-fold selectivity over CDK2. |
| PC-26367 |
CDK9 inhibitor HS34
CDK9 inhibitor
|
CDK9 inhibitor HS34 is a potent, selective CDK9 inhibitor with IC50 of 1.4 nM (CDK9/CycT1), shows 250-fold selectivity over CDK2/CycA2. |
| PC-26363 |
Vustanaciclib
CDK2/4/6 inhibitor
|
Vustanaciclib (GDC-4198, RGT-419B) is a potent CDK2/4/6 inhibitor. |
| PC-26145 |
HQY1428
cyclin K degrader
|
HQY1428 is an oral availabile cyclin K molecular glue degrader, promotes CDK12 condensation in nuclear speckles and accelerates proteasomal degradation of CDK12-cyclin K, shows potent single-agent antitumor activity and synergistic efficacy with HER2 inhibitors. |
